PMID- 36096955
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220915
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 14
IP  - 1
DP  - 2022 Sep 12
TI  - Prevalence of haplotype DQ2/DQ8 and celiac disease in children with type 1 
      diabetes.
PG  - 128
LID - 10.1186/s13098-022-00897-8 [doi]
LID - 128
AB  - Type 1 diabetes (T1D) and celiac disease (CD) coexist very often. Identification 
      of the human leukocyte antigen (HLA) DQ2/DQ8 can confirm the genetic 
      predisposition to CD. Negative result of this test allows to exclude CD with a 
      high probability. It was suggested that in individuals with higher risk of CD, 
      including T1D patients, the implementation of genetic testing should reduce the 
      number of patients requiring systematic immunological screening. The aim of this 
      study was to analyze the prevalence of different haplotypes predisposing to CD in 
      children and adolescents with previously diagnosed T1D. MATERIAL AND METHODS: A 
      retrospective analysis was performed on 166 T1D children (91 girls) in whom HLA 
      DQ2/DQ8 alleles were tested. In 9.6% CD was also diagnosed. RESULTS: In 12.7% 
      both HLA DQ2/DQ8 were negative. In 87.3% patients HLA DQ2 and/or DQ8 was 
      positive, including 27.7% patients with both haplotypes DQ2.5 and DQ8 positive. 
      In all CD patients the disease predisposing alleles were positive, while none of 
      the HLA DQ2/DQ8 negative children were diagnosed with CD. CONCLUSIONS: The 
      prevalence of HLA DQ2.5 and the HLA DQ2.5 / HLA DQ8 configuration is higher in 
      patients with T1D, and CD compared to children with T1D alone. The combination of 
      HLA DQ2 and HLA DQ8 most significantly increases the risk of developing CD. The 
      group of HLA DQ2/DQ8 negative patients with improbable CD diagnosis, is 
      relatively small. Most of T1D patients HLA DQ2/DQ8 positive need further regular 
      antibody assessment. In patients with T1D, who are at high risk of developing CD, 
      genetic testing may be considered to select those who require further systematic 
      serological evaluation. Due to its retrospective nature, the study was not 
      registered in the database of clinical trials and the Clinical trial registration 
      number is not available.
CI  - (c) 2022. The Author(s).
FAU - Zubkiewicz-Kucharska, Agnieszka
AU  - Zubkiewicz-Kucharska A
AD  - Department of Pediatric Endocrinology and Diabetology for Children and 
      Adolescents, Wroclaw Medical University, Wroclaw, Poland.
FAU - Jamer, Tatiana
AU  - Jamer T
AD  - Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical 
      University, Wroclaw, Poland. tatiana.jamer@umw.edu.pl.
FAU - Chrzanowska, Joanna
AU  - Chrzanowska J
AD  - Department of Pediatric Endocrinology and Diabetology for Children and 
      Adolescents, Wroclaw Medical University, Wroclaw, Poland.
FAU - Akutko, Katarzyna
AU  - Akutko K
AD  - Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Pytrus, Tomasz
AU  - Pytrus T
AD  - Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Stawarski, Andrzej
AU  - Stawarski A
AD  - Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Noczynska, Anna
AU  - Noczynska A
AD  - Department of Pediatric Endocrinology and Diabetology for Children and 
      Adolescents, Wroclaw Medical University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20220912
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC9465882
OTO - NOTNLM
OT  - Celiac disease
OT  - Diabetes type 1
OT  - Haplotype HLA-DQ2/DQ8
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:01
PMCR- 2022/09/12
CRDT- 2022/09/12 23:48
PHST- 2022/06/10 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/09/12 23:48 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:01 [medline]
PHST- 2022/09/12 00:00 [pmc-release]
AID - 10.1186/s13098-022-00897-8 [pii]
AID - 897 [pii]
AID - 10.1186/s13098-022-00897-8 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2022 Sep 12;14(1):128. doi: 10.1186/s13098-022-00897-8.